Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01928576
Title Phase II Anti-PD1 Epigenetic Priming Study in NSCLC.
Acronym NA_00084192
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sidney Kimmel Comprehensive Cancer Center
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Southern California Los Angeles California 90033 United States Details
Sibley Memorial Hospital Washington District of Columbia 20016 United States Details
Julie Brahmer, MD Baltimore Maryland 21224 United States Details
Julie Brahmer, MD Baltimore Maryland 21287 United States Details
UPMC Cancer Center- Hillman Cancer Center Pittsburgh Pennsylvania 15213 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field